Combined Drug Action of 2-Phenylimidazo[2,1-b]Benzothiazole Derivatives on Cancer Cells According to Their Oncogenic Molecular Signatures

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Furlan, Alessandro ^a   Roux, Benjamin ^a   Lamballe, Fabienne ^a   Conti, Filippo ^a   Issaly, Nathalie ^a   Daian, Fabrice ^a   Guillemot, Jean François ^a   Richelme, Sylvie ^a   Contensin, Magali ^a   Bosch, Joan ^b   Passarella, Daniele ^c   Piccolo, Oreste ^d   Dono, Rosanna ^a   Maina, Flavio ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d Studio di Consulenza Scientifica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CRIZOTINIB; GEFITINIB; IMATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NILOTINIB; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; TRIFLORCAS; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN INTERACTION MAPS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867154429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046738     Document Type: Article

References (52)

1. Zwick E, Bange J, Ullrich A, (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8: 17-23.
2. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
3. Hunter T, (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21: 140-146.
4. Network TCGAR, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
5. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
6. Furlan A, Stagni V, Hussain A, Richelme S, Conti F, et al. (2011) Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ 18: 1608-1616.
7. Furlan A, Lamballe F, Stagni V, Hussain A, Richelme S, et al. (2012) Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. J Hepatol 10.1016/j.jhep.2012.07.044 (2012).
8. Knudsen BS, Vande Woude G, (2008) Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 18: 87-96.
9. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105: 692-697.
10. Dancey JE, Chen HX, (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5: 649-659.
11. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844.
12. Asses Y, Leroux V, Tairi-Kellou S, Dono R, Maina F, et al. (2009) Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands. Chem Biol Drug Des 74: 560-570.
13. Cui JJ, (2007) Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Patents 17: 1035-1045.
14. Underiner TL, Herbertz T, Miknyoczki SJ, (2010) Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med Chem 10: 7-27.
15. Corso S, Comoglio PM, Giordano S, (2005) Cancer therapy: can the challenge be MET? Trends Mol Med 11: 284-292.
16. Trusolino L, Bertotti A, Comoglio PM, (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848.
17. Comoglio PM, Giordano S, Trusolino L, (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516.
18. Patane S, Pietrancosta N, Hassani H, Leroux V, Maigret B, et al. (2008) A new Met inhibitory-scaffold identified by a focused forward chemical biological screen. Biochem Biophys Res Commun 375: 184-189.
19. Furlan A, Colombo F, Kover A, Issaly N, Tintori C, et al. (2012) Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. Eur J Med Chem 47: 239-254.
20. Colombo F, Tintori C, Furlan A, Borrelli S, Christodoulou MS, et al. (2012) 'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells. Bioorg Med Chem Lett 22: 4693-4696.
21. Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, et al. (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6: 1624-1631.
22. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, et al. (2009) Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2: er11.
23. Doostdar H, Burke MD, Mayer RT, (2000) Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144: 31-38.
24. Fabian MA, Biggs WH, 3rd, Treiber DK, Atteridge CE, Azimioara MD, et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336.
25. Grisendi S, Mecucci C, Falini B, Pandolfi PP, (2006) Nucleophosmin and cancer. Nat Rev Cancer 6: 493-505.
26. Arteaga CL, (2007) HER3 and mutant EGFR meet MET. Nat Med 13: 675-677.
27. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
28. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
29. Shattuck DL, Miller JK, Carraway KL, 3rd, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68: 1471-1477.
30. Druker BJ, (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30.
31. Shoemaker RH, (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
32. Wagner EF, Nebreda AR, (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
33. Maina F, Casagranda F, Audero E, Simeone A, Comoglio P, et al. (1996) Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 87: 531-542.
34. Maina F, Hilton MC, Andres R, Wyatt S, Klein R, et al. (1998) Multiple roles for hepatocyte growth factor in sympathetic neuron development. Neuron 20: 835-846.
35. Maina F, Hilton MC, Ponzetto C, Davies AM, Klein R, (1997) Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes and Development 11: 3341-3350.
36. Maina F, Klein R, (1999) Hepatocyte growth factor- a versatile signal for developing neurons. Nature Neuroscience 2: 213-217.
37. Maina F, Pante G, Helmbacher F, Andres R, Porthin A, et al. (2001) Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell 7: 1293-1306.
38. Helmbacher F, Dessaud E, Arber S, deLapeyriere O, Henderson CE, et al. (2003) Met signaling is required for recruitment of motor neurons to PEA3-positive motor pools. Neuron 39: 767-777.
39. Segarra J, Balenci L, Drenth T, Maina F, Lamballe F, (2006) Combined Signaling through ERK, PI3K/AKT, and RAC1/p38 Is Required for Met-triggered Cortical Neuron Migration. J Biol Chem 281: 4771-4778.
40. Moumen A, Ieraci A, Patane S, Sole C, Comella JX, et al. (2007) Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner. Hepatology 45: 1210-1217.
41. Moumen A, Patane S, Porras A, Dono R, Maina F, (2007) Met acts on Mdm2 via mTOR to signal cell survival during development. Development 134: 1443-1451.
42. Lamballe F, Genestine M, Caruso N, Arce V, Richelme S, et al. (2011) Pool-specific regulation of motor neuron survival by neurotrophic support. J Neurosci 31: 11144-11158.
43. Tonges L, Ostendorf T, Lamballe F, Genestine M, Dono R, et al. (2011) Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo. J Neurochem 117: 892-903.
44. Genestine M, Caricati E, Fico A, Richelme S, Hassani H, et al. (2011) Enhanced neuronal Met signalling levels in ALS mice delay disease onset. Cell Death Dis 2: e130.
45. Clague MJ, (2011) Met receptor: a moving target. Sci Signal 4: pe40.
46. Joffre C, Barrow R, Menard L, Calleja V, Hart IR, et al. (2011) A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 13: 827-837.
47. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
48. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
49. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, et al. (2000) Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60: 5196-5203.
50. Mukherjee A, Martin SG, (2006) In vitro cytotoxicity of Phortress against colorectal cancer. Int J Oncol 29: 1287-1294.
51. Bradshaw TD, Bibby MC, Double JA, Fichtner I, Cooper PA, et al. (2002) Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 1: 239-246.
52. Hose CD, Hollingshead M, Sausville EA, Monks A, (2003) Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2: 1265-1272.